Gene-editing company CRISPR Therapeutics announced the appointment of Michael Tomsicek as its chief financial officer.
“Tomsicek is a highly accomplished CFO who brings an extensive array of financial experience to CRISPR, including a background with global public companies in corporate finance, operations management systems, and corporate collaborations and licensing,” said CRISPR Therapeutics.
“He joins CRISPR Therapeutics to oversee the company’s global finance team reporting directly to the chief executive officer.”
CRISPR said Tomsicek most recently served as CFO of Abiomed, a publicly-traded provider of medical devices with more than $400 million in sales and an $8 billion market capitalization.
Before that, he was chief financial officer at Cubist Pharmaceuticals.
Prior to Cubist, Tomsicek spent nearly eight years at General Electric Healthcare, as finance manager in global operations, and then as CFO of its ultrasound business.
“Mike’s extensive experience in global finance and operations, as well as his track record of financing clinical-stage biotech companies, will be critical as we enter our next phase of growth and begin clinical trials,” said Sam Kulkarni, President of CRISPR Therapeutics.
Tomsicek said: “I believe CRISPR Therapeutics is poised to translate its leading gene-editing platform into transformative therapies in hemoglobinopathies and cancer.
“I am enthusiastic to join CRISPR and help realize this great promise.”
Tomsicek holds a bachelor of science degree in engineering and an MBA, both from the University of Wisconsin.